Woodline Partners LP trimmed its position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) by 26.6% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 400,278 shares of the company's stock after selling 145,367 shares during the period. Woodline Partners LP owned approximately 0.30% of Centessa Pharmaceuticals worth $5,756,000 as of its most recent SEC filing.
A number of other large investors also recently added to or reduced their stakes in CNTA. GF Fund Management CO. LTD. acquired a new position in Centessa Pharmaceuticals during the fourth quarter worth $31,000. Caitong International Asset Management Co. Ltd lifted its stake in Centessa Pharmaceuticals by 15,209.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock worth $46,000 after purchasing an additional 3,194 shares in the last quarter. Osterweis Capital Management Inc. acquired a new position in Centessa Pharmaceuticals during the first quarter worth $47,000. Bank of New York Mellon Corp acquired a new position in Centessa Pharmaceuticals during the first quarter worth $147,000. Finally, Fox Run Management L.L.C. acquired a new position in Centessa Pharmaceuticals during the first quarter worth $160,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
CNTA has been the topic of a number of recent research reports. Chardan Capital reaffirmed a "buy" rating and set a $30.00 price objective on shares of Centessa Pharmaceuticals in a research report on Tuesday, August 12th. Truist Financial initiated coverage on Centessa Pharmaceuticals in a research report on Monday, July 21st. They set a "buy" rating and a $30.00 price objective on the stock. Lifesci Capital raised Centessa Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, September 3rd. Needham & Company LLC initiated coverage on Centessa Pharmaceuticals in a research report on Wednesday, May 28th. They set a "buy" rating and a $35.00 price objective on the stock. Finally, Wall Street Zen lowered Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. One equities research analyst has rated the stock with a Strong Buy rating and ten have assigned a Buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $32.44.
Check Out Our Latest Analysis on Centessa Pharmaceuticals
Insider Activity at Centessa Pharmaceuticals
In other Centessa Pharmaceuticals news, General Counsel Iqbal J. Hussain sold 20,000 shares of the firm's stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $20.01, for a total transaction of $400,200.00. Following the transaction, the general counsel owned 105,386 shares of the company's stock, valued at approximately $2,108,773.86. This trade represents a 15.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Saurabh Saha sold 55,000 shares of the firm's stock in a transaction dated Monday, July 21st. The stock was sold at an average price of $15.92, for a total value of $875,600.00. Following the transaction, the chief executive officer directly owned 221,017 shares in the company, valued at approximately $3,518,590.64. The trade was a 19.93% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 262,286 shares of company stock valued at $4,364,835. Corporate insiders own 7.09% of the company's stock.
Centessa Pharmaceuticals Stock Up 2.6%
NASDAQ:CNTA traded up $0.58 during trading hours on Thursday, hitting $22.43. The company's stock had a trading volume of 638,763 shares, compared to its average volume of 1,021,895. The stock has a market capitalization of $3.00 billion, a P/E ratio of -12.52 and a beta of 1.47. The stock has a fifty day moving average of $17.22 and a 200-day moving average of $14.76. The company has a current ratio of 10.11, a quick ratio of 10.12 and a debt-to-equity ratio of 0.32. Centessa Pharmaceuticals PLC Sponsored ADR has a 52-week low of $9.60 and a 52-week high of $23.24.
Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.03). On average, equities analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current year.
Centessa Pharmaceuticals Company Profile
(
Free Report)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
See Also
Before you consider Centessa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.
While Centessa Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
